Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-046861
Filing Date
2022-08-11
Accepted
2022-08-11 16:07:09
Documents
89
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0622_immucellcorp.htm   iXBRL 10-Q 1124871
2 AMENDMENT TO RIGHTS AGREEMENT DATED AS OF AUGUST 10, 2022 f10q0622ex4-1_immucell.htm EX-4.1 11422
3 CERTIFICATION f10q0622ex31_immucell.htm EX-31 10201
4 CERTIFICATION f10q0622ex32_immucell.htm EX-32 4958
  Complete submission text file 0001213900-22-046861.txt   6712065

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE iccc-20220630.xsd EX-101.SCH 84458
6 XBRL CALCULATION FILE iccc-20220630_cal.xml EX-101.CAL 37993
7 XBRL DEFINITION FILE iccc-20220630_def.xml EX-101.DEF 283445
8 XBRL LABEL FILE iccc-20220630_lab.xml EX-101.LAB 612102
9 XBRL PRESENTATION FILE iccc-20220630_pre.xml EX-101.PRE 300560
83 EXTRACTED XBRL INSTANCE DOCUMENT f10q0622_immucellcorp_htm.xml XML 1057333
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12934 | Film No.: 221155707
SIC: 2835 In Vitro & In Vivo Diagnostic Substances